Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
Got $5,000? 2 Top Healthcare Stocks to Buy in 2025 and Hold Forever.
Eli Lilly started 2024 on a strong note but struggled during the second half of the year. The drugmaker dealt with several ...
Wins & losses: How has Lily Wu fared in her first year as Wichita mayor?
In an interview with The Eagle, Wu expressed frustration with several city decisions in 2024 and vowed to hold bureaucracy ...
Prediction: 3 Stocks That'll Be Worth More Than Berkshire Hathaway 5 Years From Now
With that as the backdrop, here's a closer look at three names that could be worth more than Berkshire Hathaway just five ...
Pfizer succeeds in late-stage trial for colorectal cancer therapy
Pfizer (NYSE:PFE) announced Saturday that its colorectal cancer therapy Braftovi, as part of a combination regimen, reduced tumor size (confirmed objective response rate) in a late-stage trial with a ...